Physician profile
Mackenzie Burt
NPI 1699556639
$1,231.02
in general payments reported to CMS, 2019-2025
12 companies · $410 in 2025
The $410 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $822 · 2025: $410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,231.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $333.26 | 2024 | Farxiga |
| Shockwave Medical, INC | $212.72 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Bayer Healthcare Pharmaceuticals INC. | $169.18 | 2025 | |
| Boston Scientific Corporation | $143.12 | 2024 | Watchman Flx |
| Cvrx, INC. | $98.44 | 2025 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $92.75 | 2024-2025 | Camzyos, Eliquis |
| United Therapeutics Corporation | $49.55 | 2024 | Tyvaso |
| Scpharmaceuticals INC. | $39.37 | 2024-2025 | |
| Cardiva Medical, INC. | $38.70 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Biotronik INC. | $20.39 | 2025 | Orsiro Mission, Pantera Leo |
| Novo Nordisk INC | $19.91 | 2025 | Ozempic, Rybelsus |
| Amgen INC. | $13.63 | 2025 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mackenzie Burt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.